In some cases, such as Fording Canadian and the Wyeth merger with Pfizer, the merger consideration is fully taxable--your sales proceeds include both the cash received and the market value of the new stock.
In other cases, such as the Schering-Plough merger with Merck, the cash portion is treated as a redemption (unless you already owned shares in Merck.) If you owned Merck already, you have to run tests set forth in Section 302 of the Internal Revenue Code to determine if you meet the requirements to be eligible to treat the cash portion of the merger proceeds as a redemption rather than a dividend. Don't worry, we can help. Just use our Calculator for Section 302 Tests.
Our handy calculator tool will help you deal with your accounting nightmare!
Use our special BNSF calculator for the
unusual dual exchange ratios involved in
the prorated stock election for the merger
of Burlington Northern Santa Fe Corp
into Berkshire Hathaway Inc. Because
the stock election was oversubscribed,
everyone who made this election received
cash to boot. Click on the picture of the
BNSF train engine to access the calculator.
Our regular "cash to boot" calculator
has pre-filled data ready for many
recent corporate merger transactions
which had stock with "cash to boot"
Alcon (by Novartis)
Medco (by Express Scripts)
Nicor (by AGL)
Marvel (by Disney)
Schering-Plough (by Merck)
Sterling Financial (by PNC)
Wyeth (by Pfizer)
Click on the picture of the boot to
access the calculator....